Epigenetic therapy for breast cancer

International Journal of Molecular Sciences

Volumn 12, Issue 7, 2011, Pages 4465-4476

  Cai, Feng Feng ^a   Kohler, Corina ^a   Zhang, Bei ^a   Wang, Ming Hong ^b   Chen, Wei Jie ^a   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Breast cancer; DNA methylation inhibitors; Epigenetic therapy; Histone deacetylation inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' FLUORO 2' DEOXYCYTIDINE; APICIDIN; AZACITIDINE; BUTYRIC ACID; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE; CYTOTOXIC AGENT; DACINOSTAT; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; ENTINOSTAT; EPIGALLOCATECHIN GALLATE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MG 98; N PHTHALOYLTRYPTOPHAN; NUCLEOSIDE ANALOG; PACLITAXEL; ROMIDEPSIN; SHORT CHAIN FATTY ACID; TACEDINALINE; TASIDOTIN; TETRAPEPTIDE; TRAPOXIN; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; EPIGENETIC THERAPY; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENOMICS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS;

EID: 79960815926     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12074465     Document Type: Review

References (73)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics. Ca-Cancer J. Clin. 2008, 58, 71-96.
2. Kelly, K.M.; Shah, N.; Shedlosky-Shoemaker, R.; Porter, K.; Agnese, D. Living post treatment: Definitions of those with history and no history of cancer. J. Cancer Survivor. 2011, 5, 158-166.
3. Taby, R.; Issa, J.P. Cancer epigenetics. Ca-Cancer J. Clin. 2010, 60, 376-392.
4. Alvarez, R.H. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010, 12, S1.
5. Alvarez, R.H.; Valero, V.; Hortobagyi, G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28, 3366-3379.
6. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8, 286-298.
7. Handel, A.E.; Ebers, G.C.; Ramagopalan, S.V. Epigenetics: Molecular mechanisms and implications for disease. Trends Mol. Med. 2010, 16, 7-16.
8. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457-463.
9. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930-935.
10. Robertson, A.B.; Dahl, J.A.; Vågbø, C.B.; Tripathi, P.; Krokan, H.E.; Klungland, A. A novel method for the efficient and selective identification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 2011, 39, e55.
11. Voso, M.T.; D'Alò, F.; Greco, M.; Fabiani, E.; Criscuolo, M.; Migliara, G.; Pagano, L.; Fianchi, L.; Guidi, F.; Hohaus, S.; et al. Epigenetic changes in therapy-related MDS/AML. Chem. Biol. Interact. 2010, 184, 46-49.
12. Hatziapostolou, M.; Iliopoulos, D. Epigenetic aberrations during oncogenesis. Cell. Mol. Life Sci. 2011, 68, 1681-1702.
13. Bestor, T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9, 2395-2402.
14. Schaefer, M.; Hagemann, S.; Hanna, K.; Lyko, F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009, 69, 8127-8132.
15. Chen, Z.X.; Riggs, A.D. DNA methylation and demethylation in mammals. J. Biol. Chem. 2011, 286, 18347-18353.
16. Gehring, M.; Reik, W.; Henikoff, S. DNA demethylation by DNA repair. Trends Genet. 2009, 25, 82-90.
17. Cortez, C.C.; Jones, P.A. Chromatin, cancer and drug therapies. Mutat. Res. 2008, 647, 44-51.
18. Krawczyk, B.; Fabianowska-Majewska, K. Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues. Nucleos. Nucleot. Nucleic Acids 2006, 25, 1029-1032.
19. Szyf, M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 243-263.
20. Chik, F.; Szyf, M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 2011, 32, 224-232.
21. Mabaera, R.; Greene, M.R.; Richardson, C.A.; Conine, S.J.; Kozul, C.D.; Lowrey, C.H. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 2008, 111, 411-420.
22. Christman, J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21, 5483-5495.
23. Kuo, H.K.; Griffith, J.D.; Kreuzer, K.N. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res. 2007, 67, 8248-8254.
24. Li, Q.; Bartlett, D.L.; Gorry, M.C.; O'Malley, M.E.; Guo, Z.S. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol. Pharmacol. 2009, 76, 1072-1081.
25. Qu, Z.; Fu, J.; Yan, P.; Hu, J.; Cheng, S.Y.; Xiao, G. Epigenetic repression of PDZ-LIM domain-containing protein 2: Implications for the biology and treatment of breast cancer. J. Biol. Chem. 2010, 285, 11786-11792.
26. Xu, J.; Zhou, J.Y.; Tainsky, M.A.; Wu, G.S. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 2007, 67, 1203-1211.
27. Mirza, S.; Sharma, G.; Pandya, P.; Ralhan, R. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol. Cell Biochem. 2010, 342, 101-109.
28. Beumer, J.H.; Parise, R.A.; Newman, E.M.; Doroshow, J.H.; Synold, T.W.; Lenz, H.J.; Egorin, M.J. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother. Pharmacol. 2008, 62, 363-368.
29. Gowher, H.; Jeltsch, A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol. Ther. 2004, 3, 1062-1068.
30. Boothman, D.A.; Briggle, T.V.; Greer, S. Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol. Ther. 1989, 42, 65-88.
31. Yoo, C.B.; Valente, R.; Congiatu, C.; Gavazza, F.; Angel, A.; Siddiqui, M.A.; Jones, P.A.; McGuigan, C.; Marquez, V.E. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine. J. Med. Chem. 2008, 51, 7593-7601.
32. Billam, M.; Sobolewski, M.D.; Davidson, N.E. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 2010, 120, 581-592.
33. Balch, C.; Yan, P.; Craft, T.; Young, S.; Skalnik, D.G.; Huang, T.H.; Nephew, K.P. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 2005, 4, 1505-1514.
34. Schuebel, K.; Baylin, S. In living color: DNA methyltransferase caught in the act. Nat. Methods 2005, 2, 736-738.
35. Brueckner, B.; Boy, R.G.; Siedlecki, P.; Musch, T.; Kliem, H.C.; Zielenkiewicz, P.; Suhai, S.; Wiessler, M.; Lyko, F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005, 65, 6305-6311.
36. Fang, M.Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63, 7563-7570.
37. Moyers, S.B.; Kumar, N.B. Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials. Nutr. Rev. 2004, 62, 204-211.
38. Chen, D.; Milacic, V.; Chen, M.S.; Wan, S.B.; Lam, W.H.; Huo, C.; Landis-Piwowar, K.R.; Cui, Q.C.; Wali, A.; Chan, T.H., et al. Tea polyphenols, their biological effects and potential molecular targets. Histol. Histopathol. 2008, 23, 487-496.
39. Piña, I.C.; Gautschi, J.T.; Wang, G.Y.; Sanders, M.L.; Schmitz, F.J.; France, D.; Cornell-Kennon, S.; Sambucetti, L.C.; Remiszewski, S.W.; Perez, L.B., et al. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68, 3866-3873.
40. Atadja, P.; Gao, L.; Kwon, P.; Trogani, N.; Walker, H.; Hsu, M.; Yeleswarapu, L.; Chandramouli, N.; Perez, L.; Versace, R., et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64, 689-695.
41. Davis, A.J.; Gelmon, K.A.; Siu, L.L.; Moore, M.J.; Britten, C.D.; Mistry, N.; Klamut, H.; D'Aloisio, S.; MacLean, M.; Wainman, N., et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 2003, 21, 85-97.
42. Stewart, D.J.; Donehower, R.C.; Eisenhauer, E.A.; Wainman, N.; Shah, A.K.; Bonfils, C.; MacLeod, A.R.; Besterman, J.M.; Reid, G.K. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Annu. Oncol. 2003, 14, 766-774.
43. Segura-Pacheco, B.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I.; Chavez, A.; Acuña, C.; Salazar, A.M.; Lizano, M.; Dueñas-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003, 9, 1596-1603.
44. Zambrano, P.; Segura-Pacheco, B.; Perez-Cardenas, E.; Cetina, L.; Revilla-Vazquez, A.; Taja-Chayeb, L.; Chavez-Blanco, A.; Angeles, E.; Cabrera, G.; Sandoval, K., et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5, 44.
45. Marsoni, S.; Damia, G.; Camboni, G. A work in progress: The clinical development of histone deacetylase inhibitors. Epigenetics 2008, 3, 164-171.
46. Fang, M.H.; Ji, X.M. Histone modification and its application in therapy for hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009, 17, 816-820 (in Chinese).
47. Namdar, M.; Perez, G.; Ngo, L.; Marks, P.A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl. Acad. Sci. USA 2010, 107, 20003-20008.
48. Candido, E.P.; Reeves, R.; Davie, J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14, 105-113.
49. Cho, H.J.; Kim, S.Y.; Kim, K.H.; Kang, W.K.; Kim, J.I.; Oh, S.T.; Kim, J.S.; An, C.H. The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J. Surg. Oncol. 2009, 7, 49:1-49:7.
50. Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O.H.; Schimpf, A.; Giavara, S.; Sleeman, J.P.; Coco, F.L.; Nervi, C.; Pelicci, P.G., et al. Valproic aciddefines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
51. Travaglini, L.; Vian, L.; Billi, M.; Grignani, F.; Nervi, C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int. J. Biochem. Cell. Biol. 2009, 41, 225-234.
52. Kim, S.H.; Kang, H.J.; Na, H.; Lee, M.O. Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein. Breast Cancer Res. 2010, 12, R22.
53. Li, Y.; Yuan, Y.Y.; Meeran, S.M.; Tollefsbol, T.O. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol. Cancer 2010, 9, 274.
54. Stearns, V.; Zhou, Q.; Davidson, N.E. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007, 25, 659-665.
55. Xu, W.S.; Perez, G.; Ngo, L.; Gui, C.Y.; Marks, P.A. Induction of polyploidy by histone deacetylase inhibitor: A pathway for antitumor effects. Cancer Res. 2005, 65, 7832-7839.
56. Bali, P.; Pranpat, M.; Swaby, R.; Fiskus, W.; Yamaguchi, H.; Balasis, M.; Rocha, K.; Wang, H.G.; Richon, V.; Bhalla, K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 2005, 11, 6382-6389.
57. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
58. Monneret, C. Histone deacetylase inhibitors. Eur. J. Med. Chem. 2005, 40, 1-13.
59. Liu, Y.; Liggitt, D.; Fong, S.; Debs, R.J. Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types. Gene Ther. 2006, 13, 1724-1730.
60. Marshall, J.L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Kang, M.H.; Figg, W.D.; Wainer, I.; Chaissang, C.; Li, M.Z., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2002, 2, 325-332.
61. Ray, A.; Okouneva, T.; Manna, T.; Miller, H.P.; Schmid, S.; Arthaud, L.; Luduena, R.; Jordan, M.A.; Wilson, L. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res. 2007, 67, 3767-3776.
62. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 2001, 98, 87-92.
63. Im, J.Y.; Park, H.; Kang, K.W.; Choi, W.S.; Kim, H.S. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem. Biol. Interact. 2008, 172, 235-244.
64. Park, H.; Im, J.Y.; Kim, J.; Choi, W.S.; Kim, H.S. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int. J. Mol. Med. 2008, 21, 325-333.
65. Keles, E.; Lianeri, M.; Jagodziński, P.P. Apicidin suppresses transcription of 17β-hydroxysteroid dehydrogenase type 1 in endometrial adenocarcinoma cells. Mol. Biol. Rep. 2011, 38, 3355-3360.
66. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 2009, 96, 4592-4597.
67. Camphausen, K.; Burgan, W.; Cerra, M.; Oswald, K.A.; Trepel, J.B.; Lee, M.J.; Tofilon, P.J. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004, 64, 316-321.
68. Srivastava, R.K.; Kurzrock, R.; Shankar, S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol. Cancer Ther. 2010, 9, 3254-3266.
69. Xu, J.; Zhou, J.Y.; Wei, W.Z.; Philipsen, S.; Wu, G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008, 68, 6718-6726.
70. Riva, L.; Blaney, S.M.; Dauser, R.; Nuchtern, J.G.; Durfee, J.; McGuffey, L.; Berg, S.L. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin. Cancer Res. 2000, 6, 994-997.
71. Perabo, F.G.; Müller, S.C. New agents for treatment of advanced transitional cell carcinoma. Annu. Oncol. 2007, 18, 835-843.
72. Kelly, T.K.; De, Carvalho, D.D.; Jones, P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28, 1069-1078.
73. Kristensen, L.S.; Nielsen, H.M.; Hansen, L.L. Epigenetics and cancer treatment. Eur. J. Pharmacol. 2009, 625, 131-142.